Research Topics
Species | Serge MassonSummaryAffiliation: Istituto di Ricerche Farmacologiche Mario Negri Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetesFabio Fiordaliso
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milan, Italy
Life Sci 79:121-9. 2006..The absence of an additive effect, suggests a common mechanism of action, through the reduction of oxidative stress...
Anaesthesiological strategies in elective craniotomy: randomized, equivalence, open trial--the NeuroMorfeo trialGiuseppe Citerio
Neuroanaesthesia and Neurointensive Care Unit, Department of Perioperative Medicine and Intensive Care, San Gerardo Hospital, Monza, Milano, Italy
Trials 10:19. 2009..This trial, named NeuroMorfeo, aims to assess the equivalence between volatile and intravenous anaesthetics for neurosurgical procedures...
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)Serge Masson
Department of Cardiovascular Reearch, Istituto Mario Negri, Milan, Italy
J Am Coll Cardiol 52:997-1003. 2008..This study sought to evaluate the association between changes over time of N-terminal pro-brain natriuretic peptide (NT-proBNP) expressed in different ways and outcome in patients with stable and chronic heart failure (HF)...
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) dataSerge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Clin Chem 52:1528-38. 2006..This work aimed to provide a direct comparison of the prognostic value of BNP and NT-proBNP in patients with chronic and stable HF...
Incremental prognostic value of changes in B-type natriuretic peptide in heart failureRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Am J Med 119:70.e23-30. 2006..We hypothesized that B-type natriuretic peptide changes during treatment of heart failure may provide independent information on disease progression and outcome in patients enrolled in the Val-HeFT trial...
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trialLidia Staszewsky
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
J Card Fail 13:797-804. 2007..Because little information is available about the population of patients with both syndromes, we assessed the characteristics and the independent contribution of COPD to outcomes in patients with stable chronic heart failure...
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)Serge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
J Card Fail 12:375-80. 2006..In this setting, BNP remained the strongest neurohormonal prognostic factor...
Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive ratsFabio Fiordaliso
Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research, 20157 Milan, Italy
Life Sci 81:951-9. 2007..In conclusion, hypertensive rat is no more susceptible than its normotensive control to acute apoptosis induced by diabetes. Oxidative stress might be considered the common trigger for cardiac myocyte apoptosis in both conditions...
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFTRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Eur Heart J 25:292-9. 2004..Mainly because of small sample size, the predictive value of different NH has never been compared, while taking into account demographic, clinical and echocardiographic markers of risk in HF...
The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trialSerge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan, Italy
Eur J Heart Fail 12:338-47. 2010..We measured the plasma concentrations of four stable precursor fragments of neurohormonal systems in patients with chronic HF and evaluated their relationship with outcome...
Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trialsSerge Masson
Department of Cardiovascular Research, Istituto Mario Negri, Via Giuseppe La Masa 19, 20156 Milan, Italy
Circulation 125:280-8. 2012..We determined the association between changes over time in hs-cTnT and outcome in patients with chronic HF...
Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudyLidia Staszewsky
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Circ Cardiovasc Imaging 4:721-8. 2011..Angiotensin receptor blockers were proposed for reversing LA remodeling. We evaluated the effect of valsartan on LA remodeling in patients with a recent episode of AF and the effect of LA size on AF recurrence (AFr)...
Neurohormonal modulation in heart failure of ischemic etiology: correlates with left ventricular remodelingRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy
Curr Heart Fail Rep 3:157-63. 2006..Whether knowledge of biomarkers' concentration can improve the clinical outcome of patients with HF by helping in guiding and monitoring their therapy treatment is a stimulating working hypothesis still to be verified...
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT)Serge Masson
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
J Card Fail 16:964-70. 2010..We evaluated the association between PRA and outcome in patients with chronic HF treated with ACEi and beta-blockers...
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)Roberto Latini
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Circulation 106:2454-8. 2002..The long-term effects of angiotensin receptor blockers on BNP and NE in heart failure patients are not known...
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failureRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Circulation 116:1242-9. 2007..We assessed the prognostic value of circulating cardiac troponin T in patients with stable chronic HF with a traditional (cTnT) and a new precommercial highly sensitive assay (hsTnT)...
Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in ratsFabio Fiordaliso
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milan, Italy
J Mol Cell Cardiol 37:959-68. 2004..NAC effectively protects from hyperglycemia-induced myocyte cell death and compensatory hypertrophy through direct scavenging of ROS and replenishment of the intracellular glutathione content...
Valsartan for the treatment of heart failureRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche, Mario Negri, Via Eritrea 62, 20157 Milan, Italy
Expert Opin Pharmacother 5:181-93. 2004....
Predictors of Mortality in 6975 Patients With Chronic Heart Failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure Trial: Proposal for a NomogramSimona Barlera
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Circ Heart Fail 6:31-9. 2013..Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00336336...
Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trialsRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milan, Italy
Eur J Heart Fail 14:992-9. 2012..Since the role of inflammation in the progression of chronic heart failure (HF) is debated, we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF...
Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarctionSerge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
J Card Fail 10:433-41. 2004..CONCLUSION: In aged rats with small to moderate MI, eplerenone normalized diastolic relaxation, possibly through a reduction of interstitial fibrosis...
Adiponectin in chronic heart failure: influence of diabetes and genetic variantsSerge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Eur J Clin Invest 41:1330-8. 2011..We also assessed the influence of these confounders on the prognostic value of adiponectin...
Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failureSerge Masson
Department of Cardiovascular Research, Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Am J Cardiol 101:56-60. 2008..Thus, serial assessment of NT-proBNP is valuable for prognostication in chronic HF in outpatients, and, as such, a measurement at each patient visit or the following of changes in clinical stability is recommended...
Role of brain natriuretic peptide in the diagnosis and management of heart failure: current conceptsRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
J Card Fail 8:288-99. 2002..Development of rapid, accurate and affordable diagnostic methods will allow the routine monitoring of BNP in a wide spectrum of settings, from general practice to controlled clinical trials...
Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive ratNoeleen De Angelis
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri Milan, Italy
J Mol Cell Cardiol 34:1655-65. 2002....
In vivo cardioprotection by N-acetylcysteine and isosorbide 5-mononitrate in a rat model of ischemia-reperfusionLaura Calvillo
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milano
Cardiovasc Drugs Ther 17:199-208. 2003....
Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trialSerge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Circ Heart Fail 3:65-72. 2010..There is, however, only limited information on the prevalence and prognostic role of urinary albumin excretion in patients with established chronic heart failure...
Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failureSerge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Clin Chem Lab Med 40:761-3. 2002..16 pM, ratio 24) and NT-proBNP (1306 vs. 57 pM, ratio 23). We conclude that N-terminal proBNP, as assayed in the present study, correlates equally to BNP with clinical variables in patients with heart failure...
Levels of circulating pro-angiogenic cells predict cardiovascular outcomes in patients with chronic heart failureGiovanna Balconi
Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research, Milano, Italy
J Card Fail 15:747-55. 2009..A low level of PACs is associated with worse outcome in patients with coronary heart disease. However, little is known about PACs in heart failure (HF)...
An update on cardiac troponins as circulating biomarkers in heart failureSerge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156, Milan, Italy
Curr Heart Fail Rep 7:15-21. 2010..In the absence of further experimental evidences, the pathophysiologic basis for the elevation of circulating cardiac troponins in patients with stable chronic heart failure remains speculative...
Biomarkers of myocyte injury in heart failureRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Heart Fail Clin 5:529-36. 2009..The advent of a new generation of high-sensitivity immunoassays for cardiac troponins offers challenges for scientists and clinicians and will likely change the understanding and interpretation of cardiac injury...
Myocardial infarction: animal modelsStefano Chimenti
Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research, Milan, Italy
Methods Mol Med 98:217-26. 2004..Moreover, this model allows testing of the protective effects of anti-inflammatory drugs in experimental myocardial infarction...
Efficacy of aminaftone in a rat model of monocrotaline-induced pulmonary hypertensionVanessa Zambelli
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano MI, Italy
Eur J Pharmacol 667:287-91. 2011..Aminaftone may represent a novel treatment strategy of pulmonary hypertension...
Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortalitySerge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Am Heart J 165:208-15.e4. 2013..Circulating levels of n-3 PUFA, an objective estimation of exposure, have never been measured in a large cohort of patients with HF...
Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trialSerge Masson
Department of Cardiovascular Research, Istituto Mario Negri, Via Giuseppe La Masa 19, Milan, Italy
Heart 96:1909-14. 2010..Inflammation may play a significant role in the pathogenesis of atrial fibrillation (AF)...
Natriuretic peptides in acute chest pain and acute coronary syndrome: from pathophysiology to clinical and prognostic applicationsNadia Aspromonte
Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy
Coron Artery Dis 24:33-9. 2013..Plasma levels of natriuretic peptides (NPs) appear to have an important prognostic value in many clinical settings including coronary artery disease and provide additional information about cardiovascular risk...
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure TrialJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, Minn 55455, USA
Circulation 108:1306-9. 2003..The Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone levels in patients with NYHA class II through IV heart failure...
C-reactive protein in heart failure: prognostic value and the effect of valsartanInder S Anand
VA Medical Center, Minneapolis, MN 55417, USA
Circulation 112:1428-34. 2005..We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan...
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Aldo P Maggioni
ANMCO Research Center, Florence, Italy
Am Heart J 149:548-57. 2005..The aims of these subanalyses of Val-HeFT were to assess (a) the effects of valsartan in the prevention of AF, (b) the independent predictors of this event, and (c) the prognostic role of AF occurrence...
[Refractory heart failure. Antagonism of tumor necrosis factor alpha and endothelin in humans: 2 promises still to be honored]Marco Valgimigli
Cattedra di Cardiologia, , Ferrara, e Centro di Fisiopatologia Cardiovascolare
Ital Heart J Suppl 3:793-803. 2002..The mechanisms by which TNF-alpha and ET might exert their negative biological actions are discussed together with an analysis of the possible reasons why they have failed so far in human CHF...
[Recommendations for the clinical use of cardiac natriuretic peptides]Michele Emdin
Istituto di Fisiologia Clinica del CNR, Pisa
Ital Heart J Suppl 6:308-25. 2005
[The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design]Giuseppe Cacciatore
U O C di Cardiologia, Azienda Ospedaliera San Giovanni Addolorata, Roma
Ital Heart J 6:66S-74S. 2005..Therefore it seems interesting to evaluate the effect of canrenone, an aldosterone receptor blocker, on the progression of left ventricular dysfunction in patients with mild heart failure assuming standard therapy...
Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or bothRaymond T Yan
The University Health Network, University of Toronto, Toronto, Ontario, Canada
Am J Cardiol 96:698-704. 2005..Serial measurements of these neurohormones may serve as useful surrogate markers of ventricular remodeling and prognosticators for clinical risk stratification...
Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFTHenry Krum
NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University, Melbourne, Australia
Int J Cardiol 119:48-53. 2007..To address this, we retrospectively analyzed the Valsartan Heart Failure Trial (Val-HeFT) database to determine outcomes in CHF patients according to statin use at baseline...
Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)Alessandro Boccanelli
Department of Cardiology, San Giovanni Addolorata Hospital, Rome, Italy
J Cardiovasc Med (Hagerstown) 8:683-91. 2007..AREA IN-CHF was planned to investigate the effects of canrenone on progression of LV remodelling in mild HF...
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Inder S Anand
VA Medical Center and University of Minnesota, Minneapolis, Minn 55417, USA
Circulation 107:1278-83. 2003..We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over time are associated with corresponding changes in mortality and morbidity in the Valsartan Heart Failure Trial...
Recommendations for the clinical use of cardiac natriuretic peptidesMichele Emdin
Institute of Clinical Physiology, National Research Council, Pisa, Italy
Ital Heart J 6:430-46. 2005
Lung injury and recovery in a murine model of unilateral acid aspiration: functional, biochemical, and morphologic characterizationMaria Amigoni
Department of Experimental Medicine, University of Milano Bicocca and Department of Perioperative Medicine and Intensive Care, San Gerardo Hospital, Monza, Italy
Anesthesiology 108:1037-46. 2008..Most animal models developed to define its pathophysiology have focused on the acute (< or =24 h) phase of the injury. The authors describe a model of acid aspiration allowing the study of this type of lung injury over time...
Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting in-hospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosisGiovanni Battista Pedrazzini
Division of Cardiology, Cardiocentro Ticino, Lugano, Switzerland
Am J Cardiol 102:749-54. 2008..In conclusion, in symptomatic patients with severe AS, high preoperative BNP plasma level and high logES confirm their predicting value for short- and long-term outcome...
